A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Key Inclusion Criteria:

1. Histologically confirmed locally advanced, metastatic, and/or unresectable iCCA orother solid tumor with documented FGFR2/3 alteration in blood and/or tumor.

2. Previously treated with, not appropriate for, or declined standard-of-carefirst-line treatment.

3. Have measurable disease per RECIST v1.1.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

5. Have clinically acceptable local laboratory screening results (clinical chemistryand hematology) within certain limits.

6. Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), includingresolution of clinically significant laboratory abnormalities, before the first doseof study drug. Exceptions are alopecia, hypothyroidism, or type 1 diabetes mellituscontrolled with medical intervention, and paronychia controlled with localintervention.

Key Exclusion Criteria:

1. Received chemotherapy or anticancer therapies or radiotherapy within certaintimeframes before first dose of study drug.

2. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of studydrug.

3. Clinically significant corneal or retinal disorders or current evidence of retinaldetachment.

4. Received more than 2 prior FGFRi therapies

5. Active, symptomatic, or untreated brain metastases unless the participant isclinically stable and off corticosteroids for ≥2 months.